Peptides are short chains of amino acids, some forms of which, including GLP-1 drugs such as Ozempic, are approved by the Food and Drug Administration for treating diabetes and obesity. Other compounds, such as BPC-157 and GHK-Cu, are not approved and have limited human data, with some evidence coming only from animal or laboratory studies. The U.S. Department of Health and Human Services reportedly plans to allow specialty pharmacies to compound certain synthetic peptides, a controversial move given the potential risks associated with BPC-157. Experts interviewed recommend against using unapproved injectable peptides because of limited evidence, the risk of counterfeit or contaminated products, and unclear doses in the gray market. Consumer interest is growing, driven by the success of GLP-1 drugs and wellness claims made on social media.
Source: Read the original article
